<DOC>
	<DOCNO>NCT02345304</DOCNO>
	<brief_summary>To assess influence different dose strength BI 1181181 single dose kinetics midazolam ( CYP3A4 probe drug ) , warfarin ( CYP2C9 probe drug ) , omeprazole ( CYP2C19 probe drug ) digoxin ( P-gp probe drug )</brief_summary>
	<brief_title>Effect BI 1181181 Midazolam , Warfarin , Omeprazole Digoxin</brief_title>
	<detailed_description />
	<mesh_term>Digoxin</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<mesh_term>Warfarin</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>Inclusion criterion : healthy male subject age 18 50 year body mass index ( BMI ) 18.5 29.9 kg/m2 Subjects must able understand comply study requirement Exclusion criterion : Any find medical examination ( include BP , PR ECG ) deviate normal judge clinically relevant investigator Repeated measurement systolic blood pressure outside range 90 140 mmHg , diastolic blood pressure outside range 50 90 mmHg , pulse rate outside range 50 90 bpm screen Any laboratory value outside reference range investigator considers clinical relevance Any evidence concomitant disease judge clinically relevant investigator Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Cholecystectomy and/or surgery gastrointestinal tract could interfere pharmacokinetics trial medication ( except appendectomy simple hernia repair ) Diseases central nervous system ( include limit kind seizure stroke ) , relevant neurological psychiatric disorder</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>